SecBot SecBot

AMTX

AEMETIS, INC
Nasdaq· Industrial Organic Chemicals· Inc. NV· CIK 0000738214 Biotech & Drug Discovery
$1.20 −0.13 (−9.77%)
Nov 13 4:00 PM ET · prev $1.33
Market cap
$97.2M
Micro cap
Consensus
Buy
80% Buy or better · 10 analysts
Median target
$10.46
+772% · range $2.50–28.00
1 year
−33.3%
from $1.80 · Nov 17
30 days
−12.4%
from $1.37
52-week range
$1.15–3.66
−67% from high · low Nov 2
Avg volume 20D
1.85M
Nov 5 spike 16.59M
Short interest
8.45M
≈11.6% of shares · +3.8%
Days to cover
10.6
at average volume
Insider net
−$20.5K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 3 reports · 90 days
Balance 0 bearish · 1 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/3

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $20.5K.

  • InstitutionsBULLISH

    Q3 2026: 13 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    8 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.182 → −$0.190 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.8% to 8.45M shares. 10.6 days to cover, ≈11.6% of shares.

  • TrendDOWNTREND

    26% below its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 5.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
STATE STREET CORPADD1,092,810$1.9M
UBS Group AGDOUBLED459,810$818.5K
Russell Investments Group, Ltd.DOUBLED434,404$773.2K
MORGAN STANLEYDOUBLED295,524$526.0K
MARSHALL WACE, LLPTRIM174,546$310.7K
RHUMBLINE ADVISERSADD82,821$147.4K
Centiva Capital, LPADD81,918$145.8K
JPMORGAN CHASE & CODOUBLED67,940$124.3K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 80% rate it Buy or better
Strong Buy2Buy6Hold2Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +772%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 16, 2026🔒 Fresh data, subscribers only
MAINTAIN
MAINTAIN
Aug 20, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
May 22, 2026Ascendiant Capital
MAINTAIN
MAINTAINBuy
Reddit
Recent posts
All social signals and their track records

Insider ledger

Form 4
$0
bought · 0 insiders
$20.5K
sold · 1 insider
DateInsiderTypeValue
Jun 10, 2026
Simon Timothy Alan
Director
Jun 10, 2026
SELL$20.5K
Mar 19, 2026
FOSTER ANDREW B
Executive Vice President
Mar 19, 2026
AWARD$528.0K
Mar 19, 2026
ROCKETT JAMES MICHAEL
EVP, General Counsel
Mar 19, 2026
AWARD$528.0K
Mar 19, 2026
BLOCK JOHN R
Director
Mar 19, 2026
AWARD$26.4K
Mar 19, 2026
Gupta Sanjeev
Executive Vice President
Mar 19, 2026
AWARD$528.0K
Mar 19, 2026
Waltz Todd
Executive Vice President, CFO
Mar 19, 2026
AWARD$528.0K
Mar 19, 2026
MCAFEE ERIC A
Chief Executive Officer
Mar 19, 2026
AWARD$792.0K

Earnings setup

Estimates
−$0.19
EPS estimate, this quarter
−4%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.19-$0.19–-$0.19-4.4%$69.8M
Next Q-$0.17-$0.17–-$0.16+12.9%$74.5M
Current FY-$0.85-$0.85–-$0.85+6.1%$271.5M
Next FY🔒 Fresh data, subscribers only

Washington

Corporate Lobbying

10 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Short side

FINRA· Oct 30, 2026
8,448,194
shares short
+3.8%
vs prior settlement
10.6
days to cover
≈11.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 5, 2026 SEC
Aemetis reported Q3 2026 revenue of $88.2M (+49% YoY) and net income of $5.2M, a $29.0M improvement from a net loss of…
8-K · Impact 6/10
Nov 5, 2026 SEC
Aemetis reported Q3 2026 revenue of $88.2M, up 49% YoY, and net income of $5.2M ($0.07 per basic share) vs a net loss…
PRESS-RELEASE · Impact 4/10
Nov 5, 2026 Earnings
Aemetis Reports Third Quarter 2026 Financial Results
Aemetis Reports Third Quarter 2026 Financial Results
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
1,092,810 shares ($1.9M)
Sep 30, 2026 Inst.
UBS Group AG · DOUBLED
459,810 shares ($818.5K)
Sep 22, 2026 SEC
Institutional activity in AEMETIS (AMTX) during Q2 2026 was mixed: 10 buyers (net +$5.9M) vs 11 sellers (net -$4.1M)…
INST-CLUSTER · Impact 3/10
Jun 10, 2026 Insider
Simon Timothy Alan sold 10,000 shares
Director @ $2.05 ($20.5K)
Mar 19, 2026 Insider
FOSTER ANDREW B was granted 200,000 shares
Executive Vice President @ $2.64 ($528.0K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

6 filings · 1 press release · 1 bullish · 2 bearish · 1 mixed · 2 neutral
All AMTX filing & press-release reports (7)